31
Participants
Start Date
February 29, 2008
Primary Completion Date
March 31, 2010
Study Completion Date
March 31, 2010
Tanespimycin
Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
Bortezomib
Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
Columbia University Medical Center (Cumc), New York
Thomas Jefferson University, Philadelphia
University Of Virginia Health System, Charlottesville
Wake Forest Univ Health Sciences, Winston-Salem
Sarah Cannon Research Institute, Nashville
Tennessee Cancer Specialists, Knoxville
Henry Ford Health System Irb, Detroit
University Of Iowa Hospitals And Clinics, Iowa City
Medical College Of Wisconsin, Milwaukee
Capitol Comprehensive Cancer Care Center, Jefferson City
University Of Kansas Medical Center, Westwood
Baylor University Medical Center, Dallas
Rocky Mountain Cancer Centers, Denver
Moores Ucsd Cancer Center, La Jolla
Comprehensive Blood And Cancer Center, Bakersfield
University Of California Medical Center, San Francisco
Kaiser Permanente Oncology/Hematology, Portland
Dana-Farber Cancer Institute, Boston
Local Institution, Edmonton
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY